Direct Answer
Vertex Pharmaceuticals (VRTX) earns virtually all revenue from its cystic fibrosis drug franchise, led by Trikafta -- a CFTR modulator treating approximately 90% of CF patients at $300,000+/year in the US. Casgevy (with CRISPR Therapeutics), the first CRISPR-approved therapy, targets sickle cell disease. Suzetrigine, a non-opioid pain drug, received FDA approval in 2025. CF revenue concentration, patent expiration in the 2030s, and pipeline execution are the primary investment risks.
Vertex Pharmaceuticals (VRTX) Business & Investor Dossier
Company Snapshot
| Ticker | VRTX (NASDAQ) |
|---|---|
| Founded | 1989 |
| Headquarters | Boston, Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Business | Rare disease pharmaceutical company; dominant cystic fibrosis CFTR modulator franchise (Trikafta); gene editing therapy Casgevy (sickle cell, with CRISPR Therapeutics) |
| Notable | Near-monopoly in cystic fibrosis; Trikafta $9B+ annual revenues; Casgevy: first CRISPR-approved therapy; suzetrigine non-opioid pain (2025 FDA approval); CF patent expiry 2030s; pipeline diversification critical |
| Key Competitors | AbbVie (ABBV), AstraZeneca (AZN), bluebird bio (BLUE), Editas Medicine (EDIT), other rare disease biotechs |
What Does Vertex Pharmaceuticals Do?
Vertex Pharmaceuticals earns virtually all of its revenue from its cystic fibrosis drug franchise, led by Trikafta (CFTR modulator treating 90% of CF patients at $300,000+/year in the US). Casgevy, developed with CRISPR Therapeutics, is the first CRISPR gene-editing therapy (approved 2023 for sickle cell disease and beta-thalassemia). Suzetrigine, a novel non-opioid pain treatment, received FDA approval in January 2025. Pipeline diversification into kidney disease, pain, and other genetic conditions is essential as CF patents expire in the 2030s.
Frequently Asked Questions
What does Vertex Pharmaceuticals do and how does it make money?
Vertex is a specialty pharmaceutical company focused on rare diseases, with virtually all revenue from its cystic fibrosis drug franchise. Its CF portfolio (Trikafta, Symdeko, Orkambi, Kalydeco) addresses approximately 90% of CF patients worldwide. Trikafta (elexacaftor/tezacaftor/ivacaftor) generates the large majority of annual revenues. Vertex earns revenue through net product sales to patients and insurers globally. As a rare disease company with treatments that substantially improve lung function and quality of life, Vertex commands high prices ($300,000+ per patient per year in the US) and faces minimal competition due to the scientific complexity of developing CFTR modulators.
What is cystic fibrosis and how has Vertex transformed its treatment?
Cystic fibrosis is a genetic disease from mutations in the CFTR gene, causing defective protein that leads to thick mucus accumulation in lungs and other organs, chronic infections, progressive lung damage, and historically a life expectancy around 40 years. Before Vertex's drugs, treatment was supportive (antibiotics, airway clearance) rather than addressing the underlying defect. Vertex's CFTR modulators are small molecules acting directly on the defective protein to restore function. Trikafta works for the most common CF mutation and many others, treating approximately 90% of CF patients with substantial lung function improvements, reduced hospitalizations, and dramatically improved quality of life.
What is Casgevy and why is it significant for Vertex?
Casgevy (exagamglogene autotemcel) is a gene editing therapy developed by Vertex and CRISPR Therapeutics that received FDA approval in late 2023, making it the first approved CRISPR/Cas9 gene editing therapy. It treats sickle cell disease and transfusion-dependent beta-thalassemia by editing patients' own stem cells to produce fetal hemoglobin, compensating for defective adult hemoglobin. Clinical trials showed substantial freedom from vaso-occlusive crises and transfusion independence. Casgevy demonstrates Vertex's ability to diversify beyond CF, validates its gene therapy capabilities, and opens rare blood disorder markets. The $2.2 million list price and complex administration (one-time treatment requiring stem cell harvest and transplant) present commercial hurdles despite clinical success.
What other diseases is Vertex targeting beyond cystic fibrosis?
Vertex is diversifying across several disease areas. APOL1-mediated kidney disease: inaxaplin (VX-147) targets FSGS and other kidney diseases with APOL1 gene variants (disproportionately affecting African-American patients) -- an indication with large unmet need. Non-opioid pain: suzetrigine (VX-548) received FDA approval in January 2025 for moderate-to-severe acute pain targeting Nav1.8 sodium channels, a potential major commercial opportunity in pain management seeking non-addictive opioid alternatives. Alpha-1 antitrypsin deficiency (AATD): earlier-stage programs for this liver/lung genetic disease. These pipelines are critical as Vertex's CF franchise will eventually face patent expiration and potential generic competition in the 2030s.
What are the main risks for Vertex Pharmaceuticals?
Key risks include CF revenue concentration (virtually all current revenue from CF products; government price controls, coverage restrictions, or earlier-than-expected generic entry would be severe), pipeline execution risk (drug development is uncertain; pipeline failures can occur in late-stage trials), pricing and reimbursement pressure (CF prices of $300,000+/year attract payer pushback and drug pricing legislation risk), gene therapy commercial execution (Casgevy's high cost and administration complexity present commercial hurdles beyond clinical success), patent expiration (Trikafta key patents expire in the 2030s), and future competition from next-generation CFTR modulators or curative gene therapies.